{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:38:34Z","timestamp":1792798714223,"version":"4.5.0"},"reference-count":152,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Adverse drug reactions (ADRs) are an important and frequent cause of morbidity and mortality. ADR can be related to a variety of drugs, including anticonvulsants, anaesthetics, antibiotics, antiretroviral, anticancer, and antiarrhythmics, and can involve every organ or apparatus. The causes of ADRs are still poorly understood due to their clinical heterogeneity and complexity. In this scenario, genetic predisposition toward ADRs is an emerging issue, not only in anticancer chemotherapy, but also in many other fields of medicine, including hemolytic anemia due to glucose-6-phosphate dehydrogenase (G6PD) deficiency, aplastic anemia, porphyria, malignant hyperthermia, epidermal tissue necrosis (Lyell\u2019s Syndrome and Stevens-Johnson Syndrome), epilepsy, thyroid diseases, diabetes, Long QT and Brugada Syndromes. The role of genetic mutations in the ADRs pathogenesis has been shown either for dose-dependent or for dose-independent reactions. In this review, we present an update of the genetic background of ADRs, with phenotypic manifestations involving blood, muscles, heart, thyroid, liver, and skin disorders. This review aims to illustrate the growing usefulness of genetics both to prevent ADRs and to optimize the safe therapeutic use of many common drugs. In this prospective, ADRs could become an untoward \u201cstress test,\u201d leading to new diagnosis of genetic-determined diseases. Thus, the wider use of pharmacogenetic testing in the work-up of ADRs will lead to new clinical diagnosis of previously unsuspected diseases and to improved safety and efficacy of therapies. Improving the genotype-phenotype correlation through new lab techniques and implementation of artificial intelligence in the future may lead to personalized medicine, able to predict ADR and consequently to choose the appropriate compound and dosage for each patient.<\/jats:p>","DOI":"10.3389\/fphar.2021.651720","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T09:06:42Z","timestamp":1619773602000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":60,"title":["Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine"],"prefix":"10.3389","volume":"12","author":[{"given":"Emanuele","family":"Micaglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela T.","family":"Locati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Monasky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Heilbron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pappone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7323","DOI":"10.1038\/s41598-019-43736-z","article-title":"Implications of genetic variation of common drug metabolizing enzymes and ABC transporters among the Pakistani population","volume":"9","author":"Afsar","year":"2019","journal-title":"Sci. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1161\/circulationaha.119.043132","article-title":"An international, multicentered, evidence-based reappraisal of genes reported to cause congenital long QT syndrome","volume":"141","author":"Adler","year":"2020","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2265.2011.04087.x","article-title":"Determinants and outcome of amiodarone-associated thyroid dysfunction","volume":"75","author":"Ahmed","year":"2011","journal-title":"Clin. Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nchembio847","article-title":"Natural expansion of the genetic code","volume":"3","author":"Ambrogelly","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccep.2010.10.012","article-title":"Overview of basic mechanisms of cardiac arrhythmia","volume":"3","author":"Antzelevitch","year":"2011","journal-title":"Card. Electrophysiol. Clin."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cpcardiol.2015.06.002","article-title":"Brugada syndrome: clinical, genetic, molecular, cellular, and ionic aspects","volume":"41","author":"Antzelevitch","year":"2016","journal-title":"Curr. Probl. Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.mrfmmm.2009.01.013","article-title":"Fanconi anemia and its diagnosis","volume":"668","author":"Auerbach","year":"2009","journal-title":"Mutat. Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2217\/pgs-2019-0127","article-title":"Pharmacogenetics and pharmacokinetics modeling of unexpected and extremely severe toxicities after Sorafenib intake","volume":"21","author":"Ba","year":"2020","journal-title":"Pharmacogenomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.4158\/ep08317.rar","article-title":"Treatment of type 2 diabetes mellitus with orally administered agents: advances in combination therapy","volume":"15","author":"Bain","year":"2009","journal-title":"Endocr. Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s11096-018-0711-z","article-title":"Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology","volume":"40","author":"Baldo","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/hep.29313","article-title":"Consortium of the rare diseases clinical research NetworkAcute hepatic porphyrias: recommendations for evaluation and long-term management","volume":"66","author":"Balwani","year":"2017","journal-title":"Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4110\/in.2016.16.4.256","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis associated with acetaminophen use during viral infections","volume":"16","author":"Ban","year":"2016","journal-title":"Immune Netw."},{"key":"B13","doi-asserted-by":"publisher","first-page":"138326","DOI":"10.1136\/postgradmedj-2020-138326","article-title":"Terbinafine-induced steven-johnson syndrome and toxic epidermal necrolysis (SJS\/TEN) overlap","author":"Banik","year":"2020","journal-title":"Postgrad. Med. J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2146\/ajhp160961","article-title":"Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency","volume":"75","author":"Belfield","year":"2018","journal-title":"Am J Health Syst Pharm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.drudis.2007.06.011","article-title":"Drug metabolism in the paediatric population and in the elderly","volume":"12","author":"Benedetti","year":"2007","journal-title":"Drug Discov. Today"},{"key":"B16","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijcard.2020.09.038","article-title":"Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen","volume":"324","author":"Bernardini","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood-2007-04-077412","article-title":"Glucose-6-Phosphate dehydrogenase deficiency: a historical perspective","volume":"111","author":"Beutler","year":"2008","journal-title":"Blood"},{"key":"B18","first-page":"29","article-title":"Environmental and drug factors in hepatic porphyria","volume":"100","author":"Bickers","year":"1982","journal-title":"Acta Derm Venereol. Suppl."},{"key":"B19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","article-title":"Epidemiology of adverse drug reactions in Europe: a review of recent observational studies","volume":"38","author":"Bouvy","year":"2015","journal-title":"Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2217\/pgs-2019-0085","article-title":"Pharmacogenetics and the treatment of epilepsy: what do we know?","volume":"20","author":"Bo\u017eina","year":"2019","journal-title":"Pharmacogenomics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/35093574","article-title":"A tour of structural genomics","volume":"2","author":"Brenner","year":"2001","journal-title":"Nat. Rev. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrm.2016.48","article-title":"The Fanconi anaemia pathway: new players and new functions","volume":"17","author":"Ceccaldi","year":"2016","journal-title":"Nat. Rev. Mol. Cel Biol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2337\/dc14-2769","article-title":"Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation","volume":"38","author":"Chakera","year":"2015","journal-title":"Dia Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bcp.12720","article-title":"Treatment of drug-induced seizures","volume":"81","author":"Chen","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2332\/allergolint.10-rai-0261","article-title":"Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis","volume":"59","author":"Chung","year":"2010","journal-title":"Allergol. Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung","year":"2016","journal-title":"J. Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1093\/eurheartj\/ehaa942","article-title":"Brugada syndrome genetics is associated with phenotype severity","volume":"42","author":"Ciconte","year":"2020","journal-title":"Eur. Heart J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jacep.2017.11.013","article-title":"General anesthesia attenuates Brugada syndrome phenotype expression","volume":"4","author":"Ciconte","year":"2018","journal-title":"JACC: Clin. Electrophysiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/genes11111275","article-title":"Genome-wide association study of metamizole-induced agranulocytosis in European populations","volume":"11","author":"Cismaru","year":"2020","journal-title":"Genes"},{"key":"B30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s11901-017-0363-9","article-title":"Genetic factors influencing drug-induced liver injury: do they have a role in prevention and diagnosis?","volume":"16","author":"Clare","year":"2017","journal-title":"Curr. Hepatol. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/clc.21975","article-title":"Arrhythmias in women","volume":"35","author":"Curtis","year":"2012","journal-title":"Clin. Cardiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/bmb\/ldx035","article-title":"Pharmacogenetics: a general review on progress to date","volume":"124","author":"Daly","year":"2017","journal-title":"Br. Med. Bull."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.12688\/f1000research.10101.1","article-title":"An overview of the cutaneous porphyrias","volume":"6","author":"Dawe","year":"2017","journal-title":"F1000Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2500\/aap.2019.40.4274","article-title":"Classification of hypersensitivity reactions","volume":"40","author":"Dispenza","year":"2019","journal-title":"Allergy Asthma Proc."},{"key":"B35","first-page":"69","article-title":"Drug dosing in renal disease","volume":"32","author":"Doogue","year":"2011","journal-title":"Clin. Biochem. Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"37284","DOI":"10.1038\/srep37284","article-title":"Genetic epidemiology of glucose-6-phosphate dehydrogenase deficiency in the Arab world","volume":"6","author":"Doss Priya","year":"2016","journal-title":"Sci. Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1182\/blood-2019-130142","article-title":"FA gene carrier status predisposes to myeloid neoplasms and bone marrow failure in adults","volume":"134","author":"Durrani","year":"2019","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/s0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3186328","DOI":"10.1155\/2017\/3186328","article-title":"HLA association with drug-induced adverse reactions","volume":"2017","author":"Fan","year":"2017","journal-title":"J. Immunol. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4330\/wjc.v5.i4.87","article-title":"Drugs to Be avoided in patients with long QT syndrome: focus on the anaesthesiological management","volume":"5","author":"Fazio","year":"2013","journal-title":"World J Cardiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1111\/bcp.14015","article-title":"Susceptibility to adverse drug reactions","volume":"85","author":"Ferner","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14740338.2018.1491547","article-title":"The economic burden of preventable Adverse drug reactions: a systematic review of observational studies","volume":"17","author":"Formica","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"B45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.nrleng.2015.03.021","article-title":"Pharmacogenetics of adverse reactions to antiepileptic drugs","volume":"33","author":"Fricke-Galindo","year":"2018","journal-title":"Neurolog\u00eda"},{"key":"B46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrcardio.2015.110","article-title":"Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms","volume":"13","author":"Frommeyer","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1172\/jci6816","article-title":"Interaction between succinyl CoA synthetase and the heme-biosynthetic enzyme ALAS-E is disrupted in sideroblastic anemia","volume":"105","author":"Furuyama","year":"2000","journal-title":"J. Clin. Invest."},{"key":"B48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1515\/dmpt-2015-0031","article-title":"Clinical implementation of pharmacogenetics","volume":"31","author":"Garc\u00eda-Gonz\u00e1lez","year":"2016","journal-title":"Drug Metab. Personalized Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40291-018-0330-3","article-title":"Drug-induced skin adverse reactions: the role of pharmacogenomics in their prevention","volume":"22","author":"Gerogianni","year":"2018","journal-title":"Mol. Diagn. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1101\/gr.6339607","article-title":"What is a gene, post-ENCODE? History and updated definition","volume":"17","author":"Gerstein","year":"2007","journal-title":"Genome Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1097\/00000542-200405000-00008","article-title":"Molecular genetic testing for malignant hyperthermia susceptibility","volume":"100","author":"Girard","year":"2004","journal-title":"Anesthesology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/circulationaha.117.030142","article-title":"Classification and reporting of potentially proarrhythmic common genetic variation in long QT syndrome genetic testing","volume":"137","author":"Giudicessi","year":"2018","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.anai.2016.09.443","article-title":"Antiepilepsy drugs and the immune system","volume":"117","author":"Godhwani","year":"2016","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0002-9149(91)90099-7","article-title":"Duration of the QT interval and total and cardiovascular mortality in healthy persons (the framingham heart study experience)","volume":"67","author":"Goldberg","year":"1991","journal-title":"Am. J. Cardiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pbiomolbio.2019.02.003","article-title":"The influence of HERG1a and HERG1b isoforms on drug safety screening in IPSC-CMs","volume":"149","author":"Goversen","year":"2019","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41397-020-00181-w","article-title":"Pediatric pharmacogenomics: challenges and opportunities: on behalf of the sanford children\u2019s genomic medicine consortium","volume":"21","author":"Gregornik","year":"2021","journal-title":"Pharmacogenomics J."},{"key":"B57","first-page":"653","article-title":"Porphyria cutanea tarda: comparison of cases precipitated by alcohol and estrogens","volume":"113","author":"Haberman","year":"1975","journal-title":"Can. Med. Assoc. J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaut.2013.04.002","article-title":"Genetic analysis of interferon induced thyroiditis (IIT): evidence for a key role for MHC and apoptosis related genes and pathways","volume":"44","author":"Hasham","year":"2013","journal-title":"J. Autoimmun."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/ncomms2952","article-title":"Stac3 is a component of the excitation-contraction coupling machinery and mutated in native American myopathy","volume":"4","author":"Horstick","year":"2013","journal-title":"Nat. Commun."},{"key":"B60","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.genm.2008.05.005","article-title":"Drug-induced long QT syndrome in women: review of current evidence and remaining gaps","volume":"5","author":"Hreiche","year":"2008","journal-title":"Gend. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1039\/c7mb00059f","article-title":"Identifying the common genetic networks of ADR (adverse drug reaction) clusters and developing an ADR classification model","volume":"13","author":"Hwang","year":"2017","journal-title":"Mol. Biosyst."},{"key":"B62","first-page":"1","year":"1972"},{"key":"B63","doi-asserted-by":"publisher","first-page":"176","DOI":"10.5603\/ep.2015.0025","article-title":"Amiodaron i tarczyca","volume":"66","author":"Jabrocka-Hybel","year":"2015","journal-title":"Endokrynologia Polska"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2217\/pgs-2017-0018","article-title":"Falls: the adverse drug reaction of the elderly and the impact of pharmacogenetics","volume":"18","author":"Just","year":"2017","journal-title":"Pharmacogenomics"},{"key":"B65","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2217\/pgs-2018-0008","article-title":"Narathip reamaroon, sayedmohammadreza soroushmehr, ari allyn-feuer, ivo D. Dinov, kayvan najarian, and brian D. Athey.Deep learning in pharmacogenomics: from gene regulation to patient stratification","volume":"19","author":"Kalinin","year":"2018","journal-title":"Pharmacogenomics"},{"key":"B66","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/cpt.280","article-title":"Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting","volume":"99","author":"Kalman","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B67","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12920-015-0115-z","article-title":"\u2018Defining \u201cmutation\u201d and \u201cpolymorphism\u201d in the era of personal genomics\u2019","volume":"8","author":"Karki","year":"2015","journal-title":"BMC Med. Genomics"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jtos.2015.10.002","article-title":"Stevens-johnson syndrome\/toxic epidermal necrolysis \u2013 a comprehensive review and guide to therapy. I. Systemic disease","volume":"14","author":"Kohanim","year":"2016","journal-title":"Ocul. Surf."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e12537","DOI":"10.1111\/anec.12537","article-title":"Clinical aspects of the three major genetic forms of long QT syndrome (LQT1, LQT2, LQT3)","volume":"23","author":"Kutyifa","year":"2018","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2217\/pgs-2019-0089","article-title":"MiRNAs in drug response variability: potential utility as biomarkers for personalized medicine","volume":"20","author":"Latini","year":"2019","journal-title":"Pharmacogenomics"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1161\/circresaha.117.310782","article-title":"Emerging role of precision medicine in cardiovascular disease","volume":"122","author":"Leopold","year":"2018","journal-title":"Circ. Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on stevens-johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clinic Rev. Allerg Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002018-199716010-00001","article-title":"Role of viral infections in the induction of adverse drug reactions","volume":"16","author":"Levy","year":"1997","journal-title":"Drug Saf."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/europace\/euy067","article-title":"Sex differences in cardiac arrhythmia: a consensus document of the European heart rhythm association, endorsed by the heart rhythm society and asia pacific heart rhythm society","volume":"20","author":"Linde","year":"2018","journal-title":"Europace"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1101\/gr.1006603","article-title":"Allelic variation in gene expression is common in the human genome","volume":"13","author":"Lo","year":"2003","journal-title":"Genome Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-94-011-4090-4_14","article-title":"Heart rate dependency of QT-interval in congenital and acquired prolonged ventricular repolarization: long-term analysis by holter monitoring","volume":"229","author":"Locati","year":"1999","journal-title":"Adv. Noninvasive Electrocardiogr. Monit. Tech., Develop. Cardiovasc. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccep.2019.02.009","article-title":"Arrhythmias due to inherited and acquired abnormalities of ventricular repolarization","volume":"11","author":"Locati","year":"2019","journal-title":"Card. Electrophysiol. Clin."},{"key":"B79","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ccep.2017.05.007","article-title":"Normal ventricular repolarization and QT interval","volume":"9","author":"Locati","year":"2017","journal-title":"Card. Electrophysiol. Clin."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jacc.2006.06.034","article-title":"QT interval duration remains a major risk factor in long QT syndrome patients* * editorials published in the journal of the American college of cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American college of cardiology","volume":"48","author":"Locati","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/00000542-199803000-00007","article-title":"Bayesian modeling of muscle biopsy contracture testing for malignant hyperthermia susceptibility","volume":"88","author":"Loke","year":"1998","journal-title":"Anesthesiology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1210\/jc.2014-2745","article-title":"Endoplasmic reticulum stress as a novel mechanism in amiodarone-induced destructive thyroiditis","volume":"100","author":"Lombardi","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B83","doi-asserted-by":"publisher","first-page":"FSO80","DOI":"10.4155\/fso.15.80","article-title":"Pharmacogenetics of cancer therapy: breakthroughs from beyond?","volume":"1","author":"Lu","year":"2015","journal-title":"Future Sci. OA"},{"key":"B84","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.hoc.2015.11.006","article-title":"Glucose-6-Phosphate dehydrogenase deficiency","volume":"30","author":"Luzzatto","year":"2016","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B85","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.fsigen.2019.07.010","article-title":"Genetic susceptibility in pharmacodynamic and pharmacokinetic pathways underlying drug-induced arrhythmia and sudden unexplained deaths","volume":"42","author":"Martinez-Matilla","year":"2019","journal-title":"Forensic Sci. Int. Genet."},{"key":"B86","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.hrthm.2013.01.032","article-title":"Prognostic implications of mutation-specific QTc standard deviation in congenital long QT syndrome","volume":"10","author":"Mathias","year":"2013","journal-title":"Heart Rhythm"},{"key":"B87","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.ijir.3901522","article-title":"The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy","volume":"19","author":"Mehrotra","year":"2007","journal-title":"Int. J. Impot Res."},{"key":"B88","article-title":"Fanconi anemia","volume-title":"GeneReviews\u00ae","author":"Mehta","year":"1993"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.amjmed.2016.03.022","article-title":"Stevens-johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention","volume":"129","author":"Miliszewski","year":"2016","journal-title":"Am. J. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.bja.2018.06.028","article-title":"Genetic epidemiology of malignant hyperthermia in the UK","volume":"121","author":"Miller","year":"2018","journal-title":"Br. J. Anaesth."},{"key":"B91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jclinane.2018.10.010","article-title":"Anaesthetic concerns in the patients with congenital erythropoietic porphyria for ocular surgery","volume":"54","author":"Nagarajappa","year":"2019","journal-title":"J. Clin. Anesth."},{"key":"B92","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.rce.2011.07.026","article-title":"Porfiria aguda intermitente y \u00e1cido valproico","volume":"212","author":"Noval Men\u00e9ndez","year":"2012","journal-title":"Revista Cl\u00ednica Espa\u00f1ola"},{"key":"B93","article-title":"Stevens Johnson syndrome","volume-title":"StatPearls","author":"Oakley","year":"2020"},{"key":"B94","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0163-7258(94)90066-3","article-title":"Age, environmental factors and drug metabolism","volume":"61","author":"O\u2019Mahony","year":"1994","journal-title":"Pharmacol. Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1056\/nejmc051040","article-title":"Gitelman\u2019s not-so-benign syndrome","volume":"353","author":"Pachulski","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1182\/blood-2012-03-416032","article-title":"Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone","volume":"120","author":"Pamba","year":"2012","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1093\/eurheartj\/ehp326","article-title":"New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence and clinical significance","volume":"30","author":"Pappone","year":"2009","journal-title":"Eur. Heart J."},{"key":"B98","doi-asserted-by":"publisher","first-page":"13","DOI":"10.15420\/aer.2018.73.2","article-title":"Brugada syndrome: progress in diagnosis and management","volume":"8","author":"Pappone","year":"2019","journal-title":"Arrhythm Electrophysiol. Rev."},{"key":"B99","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2019.04.008","article-title":"Heme biosynthesis and the porphyrias","volume":"128","author":"Phillips","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"B100","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/978-3-642-00663-0_17","article-title":"Pharmacogenetics of idiosyncratic adverse drug reactions","volume":"196","author":"Pirmohamed","year":"2010","journal-title":"Handbook Exp. Pharmacol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1534\/genetics.116.196956","article-title":"The evolving definition of the term \u201cgene\u201d","volume":"205","author":"Portin","year":"2017","journal-title":"Genetics"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC)endorsed by: association for European paediatric and congenital cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"key":"B103","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/s0140-6736(09)61925-5","article-title":"Porphyrias","volume":"375","author":"Puy","year":"2010","journal-title":"Lancet"},{"key":"B104","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/107424840100600202","article-title":"Importance of QT interval determination and renal function assessment during antiarrhythmic drug therapy","volume":"6","author":"Reiffel","year":"2001","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"B105","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/aln.0000000000001878","article-title":"Malignant hyperthermia in the post-genomics era","volume":"128","author":"Riazi","year":"2018","journal-title":"Anesthesiology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/3-540-29715-4_3","article-title":"Proarrhythmia","volume":"171","author":"Roden","year":"2006","journal-title":"Handb Exp. Pharmacol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1113\/jp270526","article-title":"Predicting drug-induced QT prolongation and torsades de Pointes","volume":"594","author":"Roden","year":"2016","journal-title":"J. Physiol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-015-0310-1","article-title":"Malignant hyperthermia: a review","volume":"10","author":"Rosenberg","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"B109","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/clpt.2010.314","article-title":"Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy","volume":"89","author":"Sadee","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B110","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/cpt.1568","article-title":"Pharmacogenomics clinical annotation tool (pharm CAT )","volume":"107","author":"Sangkuhl","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B112","first-page":"203","article-title":"Psychiatric symptoms associated with porphyria: a case report and brief review","volume":"29","author":"Santos","year":"2017","journal-title":"Ann. Clin. Psychiatry"},{"key":"B113","doi-asserted-by":"publisher","first-page":"575540","DOI":"10.3389\/fphar.2020.575540","article-title":"Pharmacogenetics in psychiatry: an update on clinical usability","volume":"11","author":"Schaik","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.therap.2020.02.007","article-title":"Drug repositioning for rare diseases: knowledge-based success stories","volume":"75","author":"Scherman","year":"2020","journal-title":"Therapies"},{"key":"B115","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2147\/TCRM.S47632","article-title":"Management of malignant hyperthermia: diagnosis and treatment","volume":"10","author":"Schneiderbanger","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"key":"B116","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1161\/01.cir.92.12.3381","article-title":"Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na + channel blockade and to increases in heart rate","volume":"92","author":"Schwartz","year":"1995","journal-title":"Circulation"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1161\/circulationaha.109.863209","article-title":"Prevalence of the congenital long-QT syndrome","volume":"120","author":"Schwartz","year":"2009","journal-title":"Circulation"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.4081\/gc.2015.5461","article-title":"To translate pharmacogenetics in geriatrics: towards a personalized medicine","volume":"1","author":"Seripa","year":"2015","journal-title":"Geriatr. Care"},{"key":"B119","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.gastro.2019.04.050","article-title":"Clinical guide and update on porphyrias","volume":"157","author":"St\u00f6lzel","year":"2019","journal-title":"Gastroenterology"},{"key":"B120","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.4103\/0976-500x.120957","article-title":"Clinical and economic burden of adverse drug reactions","volume":"4","author":"Sultana","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B121","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte- an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B122","doi-asserted-by":"publisher","first-page":"361","DOI":"10.17219\/acem\/58955","article-title":"Clinical, biochemical and molecular characteristics of the main types of porphyria","volume":"25","author":"Szlendak","year":"2016","journal-title":"Adv. Clin. Exp. Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/cpdd.336","article-title":"Assessment of hepatic impairment and implications for pharmacokinetics of substance use treatment","volume":"6","author":"Talal","year":"2017","journal-title":"Clin. Pharmacol. Drug Develop."},{"key":"B124","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/bs.apha.2018.04.007","article-title":"Cytochrome P450 in pharmacogenetics: an update","volume":"83","author":"Tornio","year":"2018","journal-title":"Adv. Pharmacol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/009127009803801103","article-title":"Gender differences in adverse drug reactions","volume":"38","author":"Tran","year":"1998","journal-title":"J. Clin. Pharmacol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1536\/ihj.17-686","article-title":"Persistent QT prolongation in a child with gitelman syndrome and SCN5A H558R polymorphism","volume":"59","author":"Tsukakoshi","year":"2018","journal-title":"Int. Heart J."},{"key":"B127","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.pharmthera.2017.05.001","article-title":"Drug-induced fatal arrhythmias: acquired long QT and Brugada syndromes","volume":"176","author":"Turker","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"B128","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/1744666x.2020.1729128","article-title":"Stevens-johnson syndrome\/toxic epidermal necrolysis with severe ocular complications","volume":"16","author":"Ueta","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1124\/pr.113.007450","article-title":"Idiosyncratic adverse drug reactions: current concepts","volume":"65","author":"Uetrecht","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"B130","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2478\/enr-2019-0013","article-title":"Novel insights into genetics and clinics of the HNF1A-MODY","volume":"53","author":"Valkovicova","year":"2019","journal-title":"Endocr. Regul."},{"key":"B131","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.rce.2015.02.004","article-title":"Dolor abdominal y s\u00edndrome de secreci\u00f3n inadecuada de hormona antidiur\u00e9tica, forma de presentaci\u00f3n de porfiria aguda intermitente","volume":"215","author":"Valle Feij\u00f3o","year":"2015","journal-title":"Revista Cl\u00ednica Espa\u00f1ola"},{"key":"B132","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/17431380410032634","article-title":"Genetic basis of drug\u2010induced arrhythmias","volume":"36","author":"Vos","year":"2004","journal-title":"Ann. Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.chembiol.2009.03.001","article-title":"Expanding the genetic code for biological studies","volume":"16","author":"Wang","year":"2009","journal-title":"Chem. Biol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.eplepsyres.2017.05.015","article-title":"Association between the HLA-B alleles and carbamazepine-induced SJS\/TEN: a meta-analysis","volume":"135","author":"Wang","year":"2017","journal-title":"Epilepsy Res."},{"key":"B135","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/aco.0b013e328337ffe0","article-title":"Anesthesia for patients with a history of malignant hyperthermia","volume":"23","author":"Wappler","year":"2010","journal-title":"Curr. Opin. Anaesthesiology"},{"key":"B136","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/carcin\/19.4.655","article-title":"Effect of cigarette smoke on CYP1A1, CYP1A2 and CYP2B1\/2 of nasal mucosae in F344 rats","volume":"19","author":"Wardlaw","year":"1998","journal-title":"Carcinogenesis"},{"key":"B137","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2174\/092986707780090981","article-title":"The effect of ageing on cytochrome P450 enzymes: consequences for drug biotransformation in the elderly","volume":"14","author":"Wauthier","year":"2007","journal-title":"Curr Med Chem."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s11095-017-2163-x","article-title":"Preemptive panel-based pharmacogenetic testing: the time is now","volume":"34","author":"Weitzel","year":"2017","journal-title":"Pharm. Res."},{"key":"B139","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/0004563212473278","article-title":"Role of genetic testing in the management of patients with inherited porphyria and their families","volume":"50","author":"Whatley","year":"2013","journal-title":"Ann. Clin. Biochem."},{"key":"B140","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nrd2423","article-title":"Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges","volume":"6","author":"Wilke","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/acn3.50848","article-title":"Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome","volume":"6","author":"Wong","year":"2019","journal-title":"Ann. Clin. Transl Neurol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3389\/fphar.2016.00357","article-title":"Huperzine A provides robust and sustained protection against induced seizures in Scn1a mutant mice","volume":"7","author":"Wong","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12859-019-2628-5","article-title":"Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA","volume":"20","author":"Wu","year":"2019","journal-title":"BMC Bioinformatics"},{"key":"B144","doi-asserted-by":"publisher","first-page":"75","DOI":"10.7555\/JBR.33.20180089","article-title":"The current status of malignant hyperthermia","volume":"34","author":"Yang","year":"2019","journal-title":"J. Biomed. Res."},{"key":"B145","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ymgme.2018.11.012","article-title":"Recent advances on porphyria genetics: inheritance, penetrance and molecular heterogeneity, including new modifying\/causative genes","volume":"128","author":"Yasuda","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.5858\/arpa.2016-0501-ra","article-title":"Review of clinical next-generation sequencing","volume":"141","author":"Yohe","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"key":"B147","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"B148","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/s0735-1097(03)00554-0","article-title":"Modulating effects of age and gender on the clinical course of long QT syndrome by genotype","volume":"42","author":"Zareba","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1056\/nejm199810013391404","article-title":"Influence of the genotype on the clinical course of the long-QT syndrome","volume":"339","author":"Zareba","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B150","doi-asserted-by":"publisher","first-page":"a2752","DOI":"10.1136\/bmj.a2752","article-title":"Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study","volume":"338","author":"Zhang","year":"2009","journal-title":"BMJ"},{"key":"B151","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1093\/brain\/awm096","article-title":"Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies","volume":"130","author":"Zhou","year":"2007","journal-title":"Brain A J. Neurol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41436-019-0667-y","article-title":"Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases","volume":"22","author":"Zhu","year":"2020","journal-title":"Genet. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.651720\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T09:06:53Z","timestamp":1619773613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.651720\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":152,"alternative-id":["10.3389\/fphar.2021.651720"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.651720","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"article-number":"651720"}}